Analisis Keuangan Saham MREO - Mereo BioPharma Group plc - Depositary Receipt (Common Stock) (NasdaqCM) Stock

Mereo BioPharma Group plc - Depositary Receipt (Common Stock)
US ˙ NasdaqCM ˙ US5894921072

Gambaran Umum
Mereo BioPharma Group plc, based in the United Kingdom, operates within the biopharmaceutical sector, focusing primarily on developing and commercializing innovative therapies for rare diseases. The company has a portfolio concentrating on endocrinology, oncology, and rare genetic diseases. One of their key projects includes BPS-804 (setrusumab), a treatment designed for osteogenesis imperfecta, a rare bone disorder. Mereo BioPharma also works on advancing treatments like acumapimod, aimed at addressing acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and alvelestat for alpha-1 antitrypsin deficiency, a genetic disorder that affects the lungs and liver. Their strategic approach combines in-licensing and acquiring under-prioritized programs from larger pharmaceutical companies to manage and propel these products through advanced clinical development stages.
Skor Kualitas, Nilai, dan Momentum

Kartu ini menunjukkan skor Kualitas, Nilai, dan Momentum untuk perusahaan tersebut.

Kualitas

The QualityScore is a proprietary scoring model that identifies high quality companies, based on cash generating efficiencies.

Nilai

Model penilaian eksklusif yang memberi peringkat pada perusahaan berdasarkan valuasi relatifnya. Skor berkisar antara 0 hingga 100, dengan 100 sebagai yang paling diremehkan nilainya.

Momentum

Proprietary scoring model that ranks companies on their six-month momentum.

Sentimen Dana

Skor Sentimen Dana (sebelumnya dikenal sebagai Skor Kepemilikan) adalah model kuantitatif eksklusif yang memberi peringkat pada perusahaan berdasarkan tingkat akumulasi kepemilikan.

QVM

The QVM Score is a proprietary scoring model that combines Quality, Value, and Momentum into a single metric that ranks companies from 0 to 100.

Laporan Laba Rugi: Pendapatan, Laba Operasional, Laba Bersih
  • Nilai revenue untuk Mereo BioPharma Group plc - Depositary Receipt (Common Stock) per 2025 Jun 30 adalah 0.50 MM.
  • Nilai operating income untuk Mereo BioPharma Group plc - Depositary Receipt (Common Stock) per 2025 Jun 30 adalah -44.62 MM.
  • Nilai net income untuk Mereo BioPharma Group plc - Depositary Receipt (Common Stock) per 2025 Jun 30 adalah -49.55 MM.
Period End (TTM) Revenue (MM) Operating Income (MM) Net Income (MM)
2025-06-30 0.50 -44.62 -49.55
2025-03-31 -47.31 -47.19
2024-12-31 -45.72 -43.25
2024-09-30 1.00 -38.07 -45.32
2024-06-30 1.00 -37.90 -36.85
2024-03-31 10.00 -25.65 -26.34
2023-12-31 10.00 -27.14 -29.47
2023-09-30 9.00 -34.28 -30.79
2023-06-30 9.00 -36.08 -31.70
2023-03-31 -50.12 -42.45
2022-12-31 -52.70 -42.22
2022-09-30 0.00 -50.05 -31.43
2022-06-30 0.00 -42.54 -18.52
2022-03-31 18.23 -31.74 -2.90
2021-12-31 36.46 -20.94 12.72
2021-09-30 36.46 -21.01 -7.10
2021-06-30 36.46 -21.08 -26.92
2021-03-31 18.23 -29.33 -95.27
2020-12-31 -37.57 -163.63
2020-09-30 -37.29 -153.43
2020-06-30
Laporan Laba Rugi: EPS
Period End (TTM) Earnings Per Share Basic Earnings Per Share Diluted
2025-06-30
2025-03-31 -0.31 -0.31
2024-12-31 -0.29
2024-09-30 -0.31 -0.31
2024-06-30 -0.26 -0.26
2024-03-31 -0.19 -0.19
2023-12-31 -0.22
2023-09-30 -0.24 -0.25
2023-06-30 -0.25 -0.27
2023-03-31 -0.35 -0.35
2022-12-31 -0.35
2022-09-30 -0.27 -0.37
2022-06-30 -0.16 -0.36
2022-03-31 -0.03 -0.30
2021-12-31 0.12 -0.23
2021-09-30 -0.07 -0.32
2021-06-30 -0.26 -0.39
2021-03-31 -1.10 -1.18
2020-12-31 -2.41 -2.40
2020-09-30 -3.41 -3.39
2020-06-30 -6.43 -6.38
Arus Kas: Operasi, Investasi, Pendanaan
  • Nilai cash from operating activities untuk Mereo BioPharma Group plc - Depositary Receipt (Common Stock) per 2025 Jun 30 adalah -32.92 MM.
  • Nilai cash from investing activities untuk Mereo BioPharma Group plc - Depositary Receipt (Common Stock) per 2025 Jun 30 adalah -0.32 MM.
  • Nilai kas dari aktivitas pendanaan untuk Mereo BioPharma Group plc - Depositary Receipt (Common Stock) per 2025 Jun 30 adalah -0.35 MM.
Period End (TTM) Cash From Operating Activities (MM) Cash From Investing Activities (MM) Cash From Financing Activities (MM)
2025-06-30 -32.92 -0.32 -0.35
2025-03-31 -33.17 -0.32 46.57
2024-12-31 -32.83 -0.70 46.15
2024-09-30 -30.20 -0.70 46.19
2024-06-30 -20.02 -0.70 54.69
2024-03-31 -19.88 -0.70 7.97
2023-12-31 -21.13 -0.42 7.97
2023-09-30 -28.28 0.03 8.24
2023-06-30 -41.92 0.33 0.64
2023-03-31 -46.44 0.97 0.38
2022-12-31 -48.82 1.99 0.20
2022-09-30 -43.32 1.30 -0.26
2022-06-30 -33.95 0.55 -0.65
2022-03-31 -19.59 0.07 38.50
2021-12-31 -5.24 -0.42 77.65
2021-09-30 -6.26 -0.32 70.42
2021-06-30 -7.28 -0.21 63.19
2021-03-31 -17.81 0.64 48.96
2020-12-31 -28.34 1.50 34.74
2020-09-30 -28.90 6.25 40.99
2020-06-30
Metrik Penilaian: PE, PriceToBook, PriceToTBV
  • p/e untuk Mereo BioPharma Group plc - Depositary Receipt (Common Stock) pada 2025 Jun 30 adalah -9.16.
  • p/libro untuk Mereo BioPharma Group plc - Depositary Receipt (Common Stock) pada 2025 Jun 30 adalah 7.20.
  • p/tbv untuk Mereo BioPharma Group plc - Depositary Receipt (Common Stock) pada 2025 Jun 30 adalah 7.27.
P/Book
The current closing price divided by the book value per share.
P/TBV
The current price divided by the tangible book value per share.
Period End (TTM) p/e P/Book P/TBV
2025-06-30 -9.16 7.20 7.27
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
Metrik Penilaian: EBitToEv, EBit3YrAvgToEv
  • EBIT/EV untuk Mereo BioPharma Group plc - Depositary Receipt (Common Stock) pada 2025 Jun 30 adalah -0.13.
  • EBIT (3 tahun) / EV untuk Mereo BioPharma Group plc - Depositary Receipt (Common Stock) pada 2025 Jun 30 adalah -0.10.
Period End (TTM) EBIT/EV EBIT (3y)/EV
2025-06-30 -0.13 -0.10
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30 0.00 -0.50
2022-06-30
2022-03-31 0.00 -0.53
2021-12-31
2021-09-30 0.00 -0.25
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
Efektivitas Manajemen
  • roa untuk Mereo BioPharma Group plc - Depositary Receipt (Common Stock) pada 2025 Jun 30 adalah -0.49.
  • roe untuk Mereo BioPharma Group plc - Depositary Receipt (Common Stock) pada 2025 Jun 30 adalah -0.60.
  • roic untuk Mereo BioPharma Group plc - Depositary Receipt (Common Stock) pada 2025 Jun 30 adalah -0.71.
  • croic untuk Mereo BioPharma Group plc - Depositary Receipt (Common Stock) pada 2025 Jun 30 adalah 0.21.
  • ocroic untuk Mereo BioPharma Group plc - Depositary Receipt (Common Stock) pada 2025 Jun 30 adalah -0.50.
Period End (TTM) ROA ROE ROIC (Tingkat Pengembalian Investasi Modal) CROIC OCROIC
2025-06-30 -0.49 -0.60 -0.71 0.21 -0.50
2025-03-31 -0.77 -1.01 -0.64 0.18 -0.49
2024-12-31 -0.68 -0.90 -0.57 0.23 -0.38
2024-09-30 -0.55 -0.73 -0.43 0.41 -0.24
2024-06-30 -0.30 -0.51 -0.49 -0.21 -0.37
2024-03-31 -0.52 -0.19 -0.37
2023-12-31 -0.30 -0.42 -0.46 -0.38 -0.42
2023-09-30 -0.39 -0.51 -0.50
2023-06-30 -0.32 -0.49 -0.37 -0.49 -0.47
2023-03-31 -0.43 -0.51 -0.51
2022-12-31 -0.15 -0.21 -0.33 -0.45 -0.46
2022-09-30 -0.41
2022-06-30 0.09 0.16 -0.22 -0.39 -0.39
2022-03-31 0.00 0.00 -0.04
2021-12-31 -0.43 0.12 0.65 -0.07
2021-09-30 0.00 -0.08
2021-06-30 -0.25 -1.11 -0.27 0.53 -0.07
2021-03-31 -0.87 -3.93 -0.94 0.30 -0.18
2020-12-31 -1.89 -4.06 -55.19 2.40 -9.56
2020-09-30 -1.77 -3.81 -9.46 1.10 -1.78
2020-06-30 -1.34 -2.43 -2.82 0.56 -0.58
Gross Margins
Margin Kotor
The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
Margin Keuntungan Bersih
Margin Bersih (juga dikenal sebagai Margin Keuntungan) adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Bersih. Perhitungannya adalah Pendapatan Bersih / Pendapatan.
Margin Operasi
Margin Operasi adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Operasi. Perhitungannya adalah Pendapatan Operasi / Pendapatan.
Period End (TTM) Margin Kotor Margin Keuntungan Bersih Margin Operasi
2025-06-30
2025-03-31 1.27 -43.25 -45.72
2024-12-31 1.27 -45.32 -38.07
2024-09-30 1.51 -36.85 -37.90
2024-06-30 0.71 -2.63 -2.56
2024-03-31 0.74 -2.95 -2.71
2023-12-31 0.74 -3.66 -4.44
2023-09-30 0.74 -3.66 -4.44
2023-06-30 -3.66 -4.44
2023-03-31
2022-12-31
2022-09-30
2022-06-30 0.51
2022-03-31 -0.16 0.00
2021-12-31 0.50 0.35 -0.57
2021-09-30 -0.19 0.00
2021-06-30 0.50 -0.74 -0.58
2021-03-31 0.50 -5.23 -1.61
2020-12-31
2020-09-30
2020-06-30
Pengenal dan Deskriptor
Kunci Indeks Pusat (CIK)1719714
Grupong Pang-industriya
SIC 2834 - Pharmaceutical Preparations
Other Listings
GB:0A9G US$ 1.77
DE:MAH0 € 1.45
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista